![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Taiwan Licenses Protein-Production Technology
Taiwan Licenses Protein-Production Technology
Taiwan's Development Center for Biotechnology has signed a nonexclusive research licensing deal with DSM Biologics, a unit of DSM Pharmaceutical Products, and Crucell, the companies announced.
The agreement involves Crucell and DSM's PER.C6 technology platform. Taiwan will use the PER.C6 human cell line for the in-house production of undisclosed recombinant proteins. Crucell said this license is its second Taiwanese license agreement involving recombinant protein production in a year, confirming the company's strong focus on Taiwan and Asia in general.
The PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products, including vaccines. Compared with conventional production technologies, the strengths of the PER.C6 technology lie in its good safety profile, scalability and productivity under serum-free culture conditions, according to Crucell and DSM. Crucell is using PER.C6 in its development programs for vaccines against Ebola, malaria, West Nile virus and influenza.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct